VNRX VOLITIONRX LTD

BEARISH Impact: 6/10 424B5
Horizon weeks Filed Jun 5, 2026 Processed 4d 13h ago SEC 0001477932-26-003669
Notable filing: 424B5

Price Chart

Loading chart...

Executive Summary

VolitionRx filed a preliminary prospectus supplement for a best-efforts unit offering of common stock, pre-funded warrants, and common stock purchase warrants, with Maxim Group LLC as placement agent. The offering size, price, and proceeds are all undisclosed (placeholder amounts). The company has a going-concern opinion from its auditors, a negative net tangible book value of -$33.7 million, and intends to use proceeds for working capital and to repay Lind Notes. This is a dilutive capital raise for a pre-revenue diagnostics company with a $17M market cap.

Actionable Insight

This is a dilutive capital raise for a company with a going-concern warning and negative book value. The best-efforts structure with no minimum means proceeds are uncertain. Monitor the final offering size and pricing — if the deal closes small, the cash runway extension is limited; if large, dilution is severe. The 45-day lock-up on insiders provides a temporary floor, but the overhang from existing convertible notes and warrants (~7M+ shares) remains. Avoid long exposure until the offering terms are known and the stock stabilizes.

Key Facts

  • Best-efforts offering of common stock, pre-funded warrants, and warrants; no minimum offering amount required.
  • Offering size, price, and net proceeds are all undisclosed (placeholder amounts in filing).
  • Company has a going-concern opinion from its auditors, indicating substantial doubt about ability to continue.
  • Net tangible book value as of March 31, 2026 was approximately -$33.7 million, or -$4.247 per share.
  • Proceeds to be used for research, product development, working capital, and repayment of Lind Notes ($7.5M + $2.4M secured convertible notes).
  • Stock closed at $2.00 on June 4, 2026; market cap ~$17M.
  • Existing investors may participate but have no binding commitments.
  • Placement agent fee is 7.0% of gross proceeds (3.5% for certain existing investors).
  • Executive officers and directors subject to 45-day lock-up; company subject to 45-day issuance blackout and 6-month price-reset restriction.

Financial Impact

Undisclosed offering size; proceeds placeholder. Company has -$33.7M net tangible book value and $9.9M in Lind Notes outstanding.

dilutiondebtcash

Risk Factors

  • Going-concern opinion from auditors — risk of business failure if capital raise insufficient.
  • Undisclosed offering size — actual proceeds may be far below needs, forcing additional dilutive raises.
  • Massive existing dilution overhang: ~7M+ shares from convertible notes and warrants at conversion/exercise prices well above current $2.00 stock price.
  • Best-efforts structure with no minimum — investors may not get sufficient capital to fund operations.
  • No public market for warrants/pre-funded warrants — limited liquidity for those securities.

Market Snapshot

Exchange
NYSE
Sector
In Vitro & In Vivo Diagnostic Substances
Analyst Consensus
80% bullish (10 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001477932-26-003669
Document: 0001477932-26-003669-index-headers.html0001477932-26-003669
Document: 0001477932-26-003669-index.html0001477932-26-003669
Document: 0001477932-26-003669.txt0001477932-26-003669
9 reports for VNRX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for VNRX — sortable, filterable
Type Now
Jun 9, 2026
today
424B5
BEARISH ★ 7/10
$1.38 awaiting T+5awaiting T+5$1.39 (−0.72%)
Jun 5, 2026
4d ago
424B5
BEARISH ★ 6/10
$1.79 awaiting T+5awaiting T+5$1.39 (+22.35%)
May 22, 2026
18d ago
8-K
BEARISH ★ 7/10
$2.94 $2.32▲ +21.09%▲ +22.30%$1.39 (+52.72%)
May 14, 2026
26d ago
8-K
NEUTRAL ★ 4/10
$2.00 $3.13▲ +56.50%▲ +55.54%$1.39 (−30.50%)
Apr 30, 2026
5w ago
10-K/A
NEUTRAL ★ 2/10
$2.43 $2.25▼ −7.41%▼ −9.75%$1.39 (−42.80%)
Apr 28, 2026
6w ago
8-K
NEUTRAL ★ 3/10
$2.64 $2.49▼ −5.68%▼ −8.79%$1.39 (−47.35%)
Apr 23, 2026
6w ago
8-K
BEARISH ★ 8/10
$2.80 $2.64▲ +5.71%▲ +7.19%$1.39 (+50.36%)
Apr 17, 2026
7w ago
8-K
NEUTRAL ★ 4/10
$3.20 $2.72▼ −14.88%▼ −15.79%$1.39 (−56.56%)
Mar 31, 2026
10w ago
8-K
MIXED ★ 6/10
$4.00 $3.45▼ −13.80%▼ −17.57%$1.39 (−65.25%)
Showing 9 of 9

US Market Status

Market Closed — Opens in 3h 51m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access